Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Research & Development: 2020-2025

Historic Research & Development for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Sep 2025 value amounting to $3.8 million.

  • Maravai Lifesciences Holdings' Research & Development fell 18.28% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.2 million, marking a year-over-year decrease of 5.60%. This contributed to the annual value of $19.2 million for FY2024, which is 11.23% up from last year.
  • Latest data reveals that Maravai Lifesciences Holdings reported Research & Development of $3.8 million as of Q3 2025, which was down 21.26% from $4.9 million recorded in Q2 2025.
  • In the past 5 years, Maravai Lifesciences Holdings' Research & Development ranged from a high of $9.2 million in Q4 2021 and a low of $1.9 million during Q2 2021.
  • Its 3-year average for Research & Development is $4.6 million, with a median of $4.6 million in 2023.
  • As far as peak fluctuations go, Maravai Lifesciences Holdings' Research & Development spiked by 339.01% in 2021, and later crashed by 45.44% in 2022.
  • Maravai Lifesciences Holdings' Research & Development (Quarterly) stood at $9.2 million in 2021, then plummeted by 45.44% to $5.0 million in 2022, then dropped by 8.32% to $4.6 million in 2023, then declined by 0.72% to $4.6 million in 2024, then fell by 18.28% to $3.8 million in 2025.
  • Its Research & Development was $3.8 million in Q3 2025, compared to $4.9 million in Q2 2025 and $4.9 million in Q1 2025.